(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
The most effective method to Refresh the Infotainment Framework in the Volvo XC40 - 2Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- 3Building an Individual Brand: Illustrations from Powerhouses
- 46 Vehicle Rental Administrations: Pick Your Ideal Ride
- 5These Are the Journalists Israel Has Killed Since the Start of the Iran War
- Home Machine Basics: An Exhaustive Purchasing Guide
- Hezbollah fires over 600 times at Israel, IDF troops over last 24 hours
- A Manual for SUVs with Less Noteworthy Gas Mileage
- Find the Excellence of Old style Expressive dance: Encountering the Effortlessness and Polish of Dance
- 6 Fledgling Cameras for 2024: Ideal for New Photographic artists
- Building a Flourishing Business: Illustrations from Business people
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- See the metal guts of a satellite in this wild X-ray view | Space photo of the day for Dec. 4, 2025
- Clones of Stumpy, Washington D.C.'s beloved cherry blossom tree, have flowered for the first time
